Masunaga S, Ono K, Hori H, Suzuki M, Kinashi Y, Takagaki M, Kasai S, Nagasawa H, Uto Y
Radiation Oncology Research Laboratory, Kyoto University, Osaka, Japan.
Br J Radiol. 2000 Sep;73(873):978-86. doi: 10.1259/bjr.73.873.11064652.
C3H/He mice bearing SCC VII tumours received 5-bromo-2'-deoxyuridine (BrdU) continuously for 5 days via implanted mini-osmotic pumps to label all proliferating (P) cells. The mice then received gamma-ray irradiation, or administration of tirapazamine (TPZ), cisplatin or bleomycin. At various time points after each treatment, tumour-bearing mice were irradiated with a series of test doses of gamma-rays, while alive or after being killed, to obtain hypoxic fractions (HFs) in the tumours. Immediately after gamma-ray test irradiation, the tumours were excised, minced and trypsinized. Tumour cell suspensions obtained were incubated with cytochalasin-B, a cytokinesis blocker, and the micronucleus (MN) frequency in cells without BrdU labelling (i.e. quiescent (Q) cells) was determined using immunofluorescence staining for BrdU. MN frequency in the total (P + Q) tumour cells was determined from the tumours that were not pre-treated with BrdU. MN frequency of BrdU-unlabelled cells was then used to calculate the surviving fraction of the unlabelled cells from the regression line for the relationship between the MN frequency and the surviving fraction of total tumour cells. TPZ and cisplatin reduced the HF after treatment, especially in Q cells, and this tendency was particularly marked with TPZ. In contrast, bleomycin increased the HF after treatment. Both reoxygenation following gamma-ray irradiation or bleomycin treatment and a subsequent return to pre-treatment levels of HF following TPZ or cisplatin treatment (rehypoxiation) occurred more rapidly in total (P + Q) cells than in Q cells. Based on our previous report that total (P + Q) and Q cells within this tumour have large acutely and chronically HFs, respectively, we conclude that acute hypoxic cells play a major role in reoxygenation and rehypoxiation in SCC VII tumours.
携带SCC VII肿瘤的C3H/He小鼠通过植入的微型渗透泵连续5天接受5-溴-2'-脱氧尿苷(BrdU),以标记所有增殖(P)细胞。然后,这些小鼠接受γ射线照射,或给予替拉扎明(TPZ)、顺铂或博来霉素。在每次治疗后的不同时间点,对荷瘤小鼠进行一系列γ射线测试剂量的照射,在存活时或处死之后,以获得肿瘤中的缺氧分数(HFs)。在γ射线测试照射后,立即切除肿瘤,切碎并进行胰蛋白酶消化。将获得的肿瘤细胞悬液与细胞松弛素B(一种胞质分裂阻滞剂)一起孵育,并使用针对BrdU的免疫荧光染色来测定未标记BrdU的细胞(即静止(Q)细胞)中的微核(MN)频率。从未用BrdU预处理的肿瘤中确定总(P + Q)肿瘤细胞中的MN频率。然后,根据MN频率与总肿瘤细胞存活分数之间关系的回归线,使用未标记BrdU细胞的MN频率来计算未标记细胞的存活分数。TPZ和顺铂在治疗后降低了HF,尤其是在Q细胞中,并且这种趋势在TPZ中尤为明显。相比之下,博来霉素在治疗后增加了HF。γ射线照射或博来霉素治疗后的再氧合以及随后TPZ或顺铂治疗后HF恢复到治疗前水平(再缺氧)在总(P + Q)细胞中比在Q细胞中发生得更快。基于我们之前的报告,即该肿瘤内的总(P + Q)细胞和Q细胞分别具有较大的急性和慢性HF,我们得出结论,急性缺氧细胞在SCC VII肿瘤的再氧合和再缺氧中起主要作用。